Affinage

CDH13

Cadherin-13 · UniProt P55290

Length
713 aa
Mass
78.3 kDa
Annotated
2026-04-28
100 papers in source corpus 25 papers cited in narrative 24 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CDH13 (T-cadherin) is a GPI-anchored atypical cadherin that functions as a vascular sequestration receptor for high-molecular-weight adiponectin, a tumor suppressor silenced by promoter hypermethylation in diverse cancers, and a modulator of inhibitory synaptic transmission in the brain (PMID:11642747, PMID:22815927, PMID:30165120). On vascular endothelium, CDH13 sequesters circulating adiponectin, as demonstrated by markedly elevated serum adiponectin in Cdh13-knockout mice that is reversed by combined adiponectin/Cdh13 bideficiency (PMID:22815927); in pancreatic β-cells, CDH13 localizes to insulin secretory granules and is required for normal second-phase glucose-stimulated insulin secretion (PMID:21975561). CDH13 suppresses tumor growth by promoting apoptosis through AKT/FoxO3a hypophosphorylation and downregulation of BCL-2 family anti-apoptotic proteins, and its expression is frequently extinguished by promoter CpG methylation maintained by a UHRF1/PRMT5 complex and counteracted by Pol β-mediated base excision repair demethylation (PMID:23625515, PMID:11389090, PMID:26597461, PMID:32641859). In the hippocampus, CDH13 is restricted to presynaptic terminals of GABAergic inhibitory synapses, and its loss increases inhibitory drive onto CA1 pyramidal neurons, shifting excitatory/inhibitory balance (PMID:30165120).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2000 Medium

    Whether CDH13 influences cell proliferation was unknown; forced expression in neuroblastoma cells abolished the mitogenic response to EGF, establishing CDH13 as a growth-suppressive molecule.

    Evidence CDH13 cDNA transfection into T-cadherin-negative neuroblastoma lines with EGF proliferation assay

    PMID:10737605

    Open questions at the time
    • Mechanism linking GPI-anchored CDH13 to intracellular EGF signaling not defined
    • No loss-of-function complement
  2. 2001 High

    The structural basis of CDH13's unusual biology was clarified: unlike classical cadherins, CDH13 is anchored exclusively by a GPI moiety and lacks a cytoplasmic domain, explaining its inability to directly engage catenin signaling.

    Evidence Biochemical/structural characterization of GPI anchor, replicated across multiple labs

    PMID:11642747

    Open questions at the time
    • How GPI-anchored CDH13 transduces signals intracellularly remains unresolved
    • No crystal structure of the full extracellular domain
  3. 2001 High

    Epigenetic silencing of CDH13 was established as a general cancer mechanism when promoter hypermethylation was shown to cause transcriptional shutdown in breast and lung cancers, reversible by 5-aza-2′-deoxycytidine.

    Evidence Methylation-specific PCR, RT-PCR, and demethylation rescue across multiple cancer cell lines

    PMID:11389090 PMID:12067979 PMID:9737784

    Open questions at the time
    • Identity of the methyltransferases responsible was unknown at this stage
    • Whether methylation is a driver or passenger in tumorigenesis was unresolved
  4. 2011 High

    CDH13's metabolic role was expanded beyond vasculature: CDH13 localizes to insulin secretory granules in β-cells and is required for second-phase glucose-stimulated insulin secretion, independent of adiponectin.

    Evidence Immunohistochemistry, electron microscopy, hyperglycemic clamp, and glucose-stimulated insulin secretion in Cdh13-KO mice and isolated islets

    PMID:21975561

    Open questions at the time
    • Molecular mechanism by which CDH13 facilitates granule exocytosis is unknown
    • Whether GPI-anchor cleavage releases CDH13 into the granule lumen was not tested
  5. 2012 High

    The long-debated question of whether CDH13 is a signaling receptor or a sequestration site for adiponectin was resolved: genetic epistasis in bideficient mice showed CDH13 sequesters high-molecular-weight adiponectin on vascular endothelium rather than transducing its signal.

    Evidence T-cad−/−, adiponectin/T-cad double-KO mice; serum adiponectin ELISA; OVA-challenge and ozone pulmonary models

    PMID:22815927 PMID:23755285

    Open questions at the time
    • Fate of sequestered adiponectin (internalization vs surface retention) not determined
    • Tissue-specific contribution of endothelial vs other cell CDH13 pools not dissected
  6. 2013 High

    CDH13's tumor-suppressive signaling was mechanistically delineated: re-expression in melanoma causes AKT/FoxO3a hypophosphorylation, loss of BCL-2/BCL-x/Clusterin, and apoptosis sensitization, while NF-κB, TCF/LEF, and mTOR pathways are excluded.

    Evidence CDH13 expression in melanoma cells; xenograft growth; Western blot for AKT, FoxO3a, BCL-2 family; transcriptional reporter assays; CD95/Fas apoptosis assay

    PMID:23625515

    Open questions at the time
    • Proximal signal transduction from GPI-anchored CDH13 to AKT inhibition unknown
    • No identification of a co-receptor or lipid-raft partner mediating signal relay
  7. 2013 High

    Transcriptional repression of CDH13 was linked to a specific transcription factor: BRN2 directly binds the CDH13 promoter at −219 bp and suppresses transcription, promoting melanoma invasion.

    Evidence EMSA for BRN2 binding element, reporter assay, reciprocal BRN2 overexpression/siRNA with CDH13 measurement

    PMID:23069940

    Open questions at the time
    • Whether BRN2-mediated repression cooperates with DNA methylation was not tested
    • Relevance beyond melanoma undetermined
  8. 2015 Medium

    The epigenetic machinery responsible for CDH13 methylation was identified: UHRF1 and PRMT5 form a complex that maintains CDH13 promoter methylation, and combined DNA methylation plus histone modification inhibition fully restores expression.

    Evidence Co-immunoprecipitation of UHRF1/PRMT5; methylation-specific PCR; 5-Aza-CdR + TSA dual treatment in endometrial carcinoma cells

    PMID:26597461

    Open questions at the time
    • No reciprocal IP or endogenous complex validation
    • Whether PRMT5 acts via histone arginine methylation at CDH13 locus specifically was not shown
  9. 2017 Medium

    CDH13's role in addiction-relevant behavior was established: Cdh13-KO rats show enhanced cue-induced reinstatement of cocaine seeking without altered conditioned place preference, dissociating CDH13 from drug reward per se and linking it to drug-cue associative learning.

    Evidence Cdh13-KO rat; intravenous cocaine self-administration, cue-induced reinstatement, conditioned place preference, locomotor assays

    PMID:28387990

    Open questions at the time
    • Circuit-level mechanism (which brain region and synapse type) not identified
    • Whether the phenotype maps to GABAergic synapse dysfunction was not tested
  10. 2018 Medium

    CDH13's neural circuit function was defined: in adult hippocampus CDH13 is restricted to presynaptic GABAergic terminals, and its loss increases inhibitory drive onto CA1 pyramidal neurons, shifting excitatory/inhibitory balance.

    Evidence Cdh13-KO mouse; hippocampal expression localization; electrophysiology-derived inhibitory drive measurement; serotonergic neuron migration analysis

    PMID:30165120

    Open questions at the time
    • Whether CDH13 acts as a synapse-organizing molecule or modulates GABA release probability is unknown
    • Causal link between hippocampal E/I shift and behavioral phenotypes not established
  11. 2020 Medium

    An active demethylation pathway for CDH13 was discovered: DNA polymerase β promotes CDH13 expression through BER-dependent demethylation of its promoter, and CDH13 is the functional effector of Pol β's anti-migratory and anti-angiogenic activity.

    Evidence Pol β overexpression/knockdown in cancer cells and xenografts; CDH13 KD rescue; CDH13 promoter methylation analysis; migration, invasion, and tube formation assays

    PMID:32641859

    Open questions at the time
    • Whether Pol β acts directly at the CDH13 locus via TET-BER or passive demethylation not distinguished
    • Single lab finding
  12. 2024 Medium

    CDH13 re-expression was shown to overcome drug resistance in imatinib-resistant CML by inhibiting NF-κB signaling and inducing apoptosis, expanding CDH13's tumor-suppressive role to hematological malignancies.

    Evidence saRNA-mediated CDH13 activation in BCR-ABL1-independent resistant CML cells; NF-κB pathway analysis; apoptosis and colony assays; LNP-saRNA xenograft

    PMID:39179585

    Open questions at the time
    • Mechanism by which CDH13 inhibits NF-κB (direct vs indirect) not resolved
    • Contrast with earlier melanoma finding excluding NF-κB suggests context-dependence that is unexplained

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a GPI-anchored protein lacking a cytoplasmic domain transduces intracellular signals to inhibit AKT, regulate NF-κB, and modulate synaptic function remains the central unresolved question; no co-receptor, lipid-raft partner, or signaling intermediary has been identified.
  • No co-receptor or transmembrane partner identified
  • No structural model of the CDH13 ectodomain at atomic resolution
  • Tissue-specific signaling outputs (endothelium vs neuron vs β-cell) not mechanistically reconciled

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 4 GO:0098631 cell adhesion mediator activity 2
Localization
GO:0005886 plasma membrane 2 GO:0031410 cytoplasmic vesicle 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-5357801 Programmed Cell Death 3
Partners
ADIPOQBRN2POLBPRMT5UHRF1

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2000 CDH13/T-cadherin, when transfected into T-cadherin-negative neuroblastoma cells (TGW and NH-12), abolished the mitogenic proliferative response to epidermal growth factor, identifying it as a negative regulator of EGF-driven neural cell growth. Transfection of CDH13 cDNA expression vector into neuroblastoma cells, proliferation assay with EGF stimulation Journal of neurochemistry Medium 10737605
2001 CDH13/T-cadherin is anchored to the cell surface membrane exclusively through a glycosyl phosphatidylinositol (GPI) moiety, lacking a cytoplasmic domain and transmembrane region, distinguishing it structurally from classical cadherins. Structural/biochemical characterization reviewed; GPI-anchor confirmed by domain analysis Histology and histopathology High 11642747
2001 Forced expression of T-cadherin (CDH13) in A549 human lung cancer cells (alveolar type-II characteristics) suppressed surfactant protein D (SP-D) mRNA and protein expression, demonstrating CDH13-mediated transcriptional downregulation of SP-D in bronchioloalveolar cells. Transfection of T-cadherin expression vector into A549 cells; RT-PCR and Western immunoblotting for SP-D Virchows Archiv Medium 11355171
2001 Aberrant promoter methylation of the CDH13 gene causes transcriptional silencing; treatment with the demethylating agent 5-aza-2'-deoxycytidine restores CDH13 expression in methylated breast and lung cancer cell lines, confirming promoter methylation as the epigenetic mechanism of silencing. Methylation-specific PCR, RT-PCR, 5-aza-2'-deoxycytidine demethylation rescue Cancer research High 11389090 12067979 9737784
2002 CDH13 promoter activity was confirmed by luciferase reporter assay, establishing that the 5' region of CDH13 functions as an active promoter susceptible to epigenetic silencing. Luciferase reporter assay Cancer research Medium 12067979
2013 CDH13 expression is a direct transcriptional target of the repressor BRN2 in melanoma cells; BRN2 binds the CDH13 promoter at a defined element (-219 bp upstream of start codon, sequence 5'-CATGCAAAA-3') and suppresses CDH13 transcription, contributing to loss of T-cadherin and increased melanoma invasion. Reporter gene assay, electrophoretic mobility shift assay (EMSA), BRN2 overexpression and siRNA knockdown with CDH13 mRNA/protein measurement Laboratory investigation High 23069940
2013 Loss of T-cadherin (CDH13) in melanoma promotes tumor growth by desensitizing cells to apoptosis; restoration of T-cadherin expression causes AKT and FoxO3a hypophosphorylation, downregulation of anti-apoptotic molecules BCL-2, BCL-x and Clusterin, and sensitization to CD95/Fas-induced apoptosis, while NFκB, TCF/LEF and mTOR signaling are not part of this pathway. T-cadherin expression in melanoma cells; in vivo xenograft tumor growth; Western blot for AKT, FoxO3a, BCL-2, BCL-x, Clusterin; transcriptional activity assays for CREB, AP-1, NFκB, TCF/LEF, mTOR; CD95/Fas apoptosis assay Molecular carcinogenesis High 23625515
2011 T-cadherin (Cdh13) localizes to insulin secretory granules in mouse and human pancreatic β-cells, and Cdh13-knockout mice exhibit impaired glucose-induced second-phase insulin secretion in vivo and in vitro without altered islet architecture, first-phase release, or insulin content, demonstrating a role for CDH13 in insulin granule function independent of adiponectin interaction. Immunohistochemistry, electron microscopy, RFP/GFP co-targeting in isolated β-cells, glucose-stimulated insulin secretion from primary islets, hyperglycemic clamp in Tcad-KO mice, glucose tolerance testing Islets High 21975561
2012 T-cadherin (Cdh13) deficiency in mice leads to markedly elevated serum adiponectin, because adiponectin normally sequestered by endothelial T-cadherin remains free in circulation; combined adiponectin/T-cad bideficiency reverses the phenotype, demonstrating that T-cadherin acts as a vascular sequestration receptor for high-molecular-weight adiponectin rather than mediating its downstream signaling. T-cad-/-, adiponectin/T-cad bideficient mice; OVA-challenge allergic airways model; serum adiponectin ELISA; BAL cell counts; histology PloS one High 22815927 23755285
2012 CDH13 knockdown in bladder TCC 5637 cells increases cell migration, invasion, adhesion, and MMP2 expression, demonstrating that CDH13 suppresses invasiveness partly by limiting matrix metalloproteinase-2 upregulation. RNA interference knockdown of CDH13; Boyden chamber migration/invasion assay; adhesion assay; MMP2 expression by Western blot/RT-PCR Urologia internationalis Medium 23235385
2013 T-cadherin (CDH13) wild-type and missense variant proteins are processed via the canonical GPI-anchor processing pathway; protein expression and cell-surface localization are similar for wild-type and ADHD-associated missense variants, as shown in CHO and HEK293 cells. Expression of GFP-tagged wild-type and mutant CDH13 in CHO and HEK293 cells; protein expression levels and subcellular distribution imaging PloS one Medium 23936508
2015 CDH13 promoter methylation is regulated by a UHRF1/PRMT5 epigenetic complex; co-immunoprecipitation demonstrated PRMT5 binding to UHRF1, and combined treatment with 5-Aza-CdR and TSA completely reversed CDH13 promoter methylation and restored expression, indicating that both DNA methylation and histone modification cooperate in CDH13 silencing in endometrial carcinoma. Co-immunoprecipitation of UHRF1 and PRMT5; methylation-specific PCR; qRT-PCR; 5-Aza-CdR and TSA treatment Gynecologic oncology Medium 26597461
2018 CDH13 promoter methylation in cisplatin-resistant lung cancer cells (A549/DDP) suppresses CDH13 expression; demethylation with 5-Aza-CdR restores CDH13 expression, increases apoptosis, and reverses cisplatin resistance by 3.35-fold, demonstrating a causal link between CDH13 methylation and drug resistance. RT-PCR, methylation-specific PCR, MTT assay, flow cytometry apoptosis assay, 5-Aza-CdR treatment in A549 vs A549/DDP cells Oncology letters Medium 30344726
2018 MicroRNA-377 directly targets CDH13 mRNA 3'-UTR to regulate its expression; in an Alzheimer's disease cell model, CDH13 is upregulated and miR-377 is downregulated; CDH13 knockdown rescues the cell viability reduction and apoptosis increase caused by miR-377 knockdown, placing CDH13 downstream of miR-377. Dual-luciferase reporter gene assay, qRT-PCR, Western blot, CCK-8 viability assay, flow cytometry apoptosis in SH-SY5Y AD model European review for medical and pharmacological sciences Medium 29771432
2018 CDH13 knockdown during adipogenesis in 3T3-L1 cells reduces fatty acid uptake, lipid content, and induction of the adipogenic transcription factors PPARγ and C/EBPα, demonstrating that CDH13 is required for normal adipocyte differentiation at the lipid metabolism and transcription factor level. CDH13 siRNA knockdown in 3T3-L1 adipocytes; fatty acid uptake assay; lipid staining; PPARγ and C/EBPα mRNA/protein quantification International journal of obesity Medium 29467502
2020 DNA polymerase β (Pol β) suppresses cancer cell migration and invasion by promoting CDH13 expression through active DNA demethylation of the CDH13 promoter via base excision repair; CDH13 knockdown restores migratory, invasive capabilities and angiogenesis that were impaired by Pol β overexpression, placing CDH13 downstream of Pol β in the BER-demethylation pathway. Pol β overexpression and knockdown in breast/lung cancer cells and xenografts; CDH13 KD rescue; CDH13 promoter methylation assay; migration/invasion assays; tube formation assay Oncogene Medium 32641859
2022 hsa_circ_0000119 acts as a sponge for miR-142-5p to increase DNMT1 expression, which then promotes CDH13 promoter methylation and silences CDH13; CDH13 re-expression or miR-142-5p overexpression reversed the pro-tumorigenic effects of hsa_circ_0000119 in ovarian cancer cells. circRNA overexpression/silencing, luciferase reporter assay for miR-142-5p binding, DNMT1 expression, CDH13 promoter methylation assay, CDH13 rescue experiments, proliferation/migration/invasion assays Journal of biochemical and molecular toxicology Medium 36482494
2024 The lncRNA CDH13-AS2 physically binds CDH13 mRNA in human endothelial cells (confirmed by dCas13-mediated RNA immunoprecipitation); CDH13-AS2 knockout is atherogenic and CDH13-AS2 CRISPRa activation is atheroprotective, effects mediated by CDH13 mRNA stability. Four miRNAs (miR-19b-3p, miR-125b-2-3p, miR-433-3p, miR-7b-5p) bind CDH13 3'UTR and accelerate mRNA degradation; CDH13-AS2 CRISPRa neutralizes this miRNA-mediated degradation. dCas13-RNA immunoprecipitation, CRISPR/Cas9 KO and CRISPRa of CDH13-AS2, in vitro miRNA binding assay, CDH13 mRNA stability measurements, atherosclerosis plaque assay in Cdh13/Apoe double-KO mice Research square (preprint)preprint Medium 40894025
2024 Potassium dehydroandrographolide succinate (PDA) upregulates MyD88 in smooth muscle cells, which physically interacts with T-cadherin (CDH13) as demonstrated by molecular docking and co-immunoprecipitation; this MyD88/CDH13 interaction augments SMC proliferation, migration, and extracellular matrix deposition, exacerbating pathological vascular remodeling. Molecular docking simulation, co-immunoprecipitation, SMC proliferation (BrdU), Boyden chamber migration, spheroid sprouting, tube formation assays, carotid ligation mouse model Chinese journal of natural medicines Low 38278560
2024 CDH13 loss-of-function increases atherosclerotic plaque size in Cdh13/Apoe double-knockout mice on a Western diet compared to Apoe single-knockout mice, demonstrating an atheroprotective role for CDH13 in vascular biology. Cdh13/Apoe double-KO mouse model on Western diet; atherosclerotic plaque quantification Research square (preprint)preprint Medium 40894025
2024 saRNA-mediated activation of CDH13 expression in BCR-ABL1-independent imatinib-resistant CML cells inhibits the NF-κB signaling pathway and induces apoptosis, overcoming drug resistance both in vitro and in a xenograft model. saRNA targeting CDH13 promoter; qPCR and Western blot for CDH13; NF-κB pathway analysis; apoptosis assay; clone formation assay; LNP-saRNA xenograft model Cell death & disease Medium 39179585
2018 CDH13 expression is restricted to the presynaptic compartment of inhibitory GABAergic synapses in the adult hippocampus; Cdh13 knockout mice show an increased inhibitory drive onto hippocampal CA1 pyramidal neurons, causing a shift in excitatory/inhibitory balance, and CDH13 moderates the migration of serotonergic neurons in the dorsal raphe nucleus during brain development. Cdh13 KO mouse behavioral battery, transcriptome analysis of hippocampus, electrophysiology implied by description of inhibitory drive; expression localization in brain Progress in neuro-psychopharmacology & biological psychiatry Medium 30165120
2017 Cdh13 knockout rats show increased cue-induced reinstatement of cocaine seeking (instrumental conditioning) compared to wild-type, while Cdh13 deficiency does not alter conditioned place preference or locomotor response to cocaine, establishing Cdh13 as a modulator of drug-cue associative learning. Cdh13 KO rat intravenous cocaine self-administration, cue-induced reinstatement, conditioned place preference, locomotor assay Genes, brain, and behavior Medium 28387990
2005 CDH13/T-cadherin is expressed on the apical membrane of differentiating podocytes in fetal human glomeruli and becomes restricted to foot processes at the advanced capillary loop stage, implicating CDH13 in podocyte differentiation and formation of the glomerular filtration barrier. Immunohistochemistry with anti-T-/H-cadherin antiserum on human fetal kidney tissue sections; developmental staging Virchows Archiv Low 16133358

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2001 Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer research 210 11389090
2000 Expression of T-cadherin (CDH13, H-Cadherin) in human brain and its characteristics as a negative growth regulator of epidermal growth factor in neuroblastoma cells. Journal of neurochemistry 161 10737605
2009 Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Human molecular genetics 140 19304780
1998 The H-cadherin (CDH13) gene is inactivated in human lung cancer. Human genetics 138 9737784
2002 Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer research 117 12067979
2011 Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. The Journal of pathology 116 21710692
2011 A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardiometabolic outcomes. Diabetes 101 21771975
2010 Genome-wide association study for adiponectin levels in Filipino women identifies CDH13 and a novel uncommon haplotype at KNG1-ADIPOQ. Human molecular genetics 90 20876611
2007 Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 90 17873891
2012 Impact of the ADHD-susceptibility gene CDH13 on development and function of brain networks. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 75 22795700
1999 Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. International journal of oncology 72 10493953
2011 CDH13 gene coding T-cadherin influences variations in plasma adiponectin levels in the Japanese population. Human mutation 64 22065538
2001 Recent progress in T-cadherin (CDH13, H-cadherin) research. Histology and histopathology 64 11642747
2012 Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13). PloS one 62 22952603
2006 p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. Journal of cellular physiology 61 16222700
2005 Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer 61 16177988
2002 Loss of T-cadherin (CDH13, H-cadherin) expression in cutaneous squamous cell carcinoma. Laboratory investigation; a journal of technical methods and pathology 60 12177241
2004 CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer. British journal of cancer 59 14997203
2008 Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clinical cancer research : an official journal of the American Association for Cancer Research 52 18519763
2015 Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma. Gynecologic oncology 51 26597461
2008 Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. International journal of cancer 50 18729198
2006 Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral oncology 49 16807071
2004 Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer. Cancer science 49 15245595
2012 Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC cancer 45 22695491
2013 Genetic variation in CDH13 is associated with lower plasma adiponectin levels but greater adiponectin sensitivity in East Asian populations. Diabetes 44 24009259
2004 Methylation pattern of CDH13 gene in digestive tract cancers. British journal of cancer 44 15292927
2011 CDH13 is associated with working memory performance in attention deficit/hyperactivity disorder. Genes, brain, and behavior 43 21815997
2012 Role of the adiponectin binding protein, T-cadherin (Cdh13), in allergic airways responses in mice. PloS one 41 22815927
2011 A variant upstream of the CDH13 adiponectin receptor gene and metabolic syndrome in Swedes. The American journal of cardiology 36 21872196
2010 Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix. Pathology, research and practice 29 21129853
2015 Association of CDH13 genotypes/haplotypes with circulating adiponectin levels, metabolic syndrome, and related metabolic phenotypes: the role of the suppression effect. PloS one 28 25875811
2011 T-cadherin (Cdh13) in association with pancreatic β-cell granules contributes to second phase insulin secretion. Islets 28 21975561
2011 Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma. Clinical lung cancer 28 22169480
2014 CDH13 promoter SNPs with pleiotropic effect on cardiometabolic parameters represent methylation QTLs. Human genetics 27 25543204
2011 Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. The Journal of international medical research 26 21672320
2018 CDH13 promoter methylation regulates cisplatin resistance of non-small cell lung cancer cells. Oncology letters 25 30344726
2014 Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer. Asian Pacific journal of cancer prevention : APJCP 25 24998565
2012 Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients. International journal of molecular sciences 25 22942707
2018 Regulatory mechanism of microRNA-377 on CDH13 expression in the cell model of Alzheimer's disease. European review for medical and pharmacological sciences 24 29771432
2016 Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma. Journal of Cancer 24 27994665
2001 T-cadherin (CDH13, H-cadherin) expression downregulated surfactant protein D in bronchioloalveolar cells. Virchows Archiv : an international journal of pathology 24 11355171
2018 Early-life stress impairs developmental programming in Cadherin 13 (CDH13)-deficient mice. Progress in neuro-psychopharmacology & biological psychiatry 23 30165120
2013 Functional properties of rare missense variants of human CDH13 found in adult attention deficit/hyperactivity disorder (ADHD) patients. PloS one 23 23936508
2012 BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells. Laboratory investigation; a journal of technical methods and pathology 23 23069940
2020 DNA polymerase beta modulates cancer progression via enhancing CDH13 expression by promoter demethylation. Oncogene 21 32641859
2018 CDH13 abundance interferes with adipocyte differentiation and is a novel biomarker for adipose tissue health. International journal of obesity (2005) 21 29467502
2013 CDH13 genotype-dependent association of high-molecular weight adiponectin with all-cause mortality: the J-SHIPP study. Diabetes care 21 24041676
2008 Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q. Human pathology 21 18656243
2013 Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma. Molecular carcinogenesis 20 23625515
2014 Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer. Medical science monitor : international medical journal of experimental and clinical research 19 25196672
2013 Genome-wide association analysis of avian resistance to Campylobacter jejuni colonization identifies risk locus spanning the CDH13 gene. G3 (Bethesda, Md.) 18 23550144
2004 Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas. International journal of oncology 18 15289870
2015 CDH13 Polymorphisms are Associated with Adiponectin Levels and Metabolic Syndrome Traits Independently of Visceral Fat Mass. Journal of atherosclerosis and thrombosis 17 26423718
2021 A Common CDH13 Variant Is Associated with Low Agreeableness and Neural Responses to Working Memory Tasks in ADHD. Genes 16 34573337
2018 Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer. Journal of biomedical research 16 30355852
2016 Hypermethylation of CDH13, DKK3 and FOXL2 promoters and the expression of EZH2 in ovary granulosa cell tumors. Molecular medicine reports 16 27431680
2020 APOB Genotypes and CDH13 Haplotypes in the Cholesterol-Related Pathway Genes Predict Non-Small Cell Lung Cancer Survival. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 15 32238407
2018 Interactions of CDH13 gene polymorphisms and ambient PM10 air pollution exposure with blood pressure and hypertension in Korean men. Chemosphere 15 30476760
2017 Cdh13 and AdipoQ gene knockout alter instrumental and Pavlovian drug conditioning. Genes, brain, and behavior 14 28387990
2013 Role of the adiponectin binding protein, T-cadherin (cdh13), in pulmonary responses to subacute ozone. PloS one 14 23755285
2012 Downregulation of CDH13 expression promotes invasiveness of bladder transitional cell carcinoma. Urologia internationalis 14 23235385
2013 Association between CDH13 variants and cardiometabolic and vascular phenotypes in a Korean population. Yonsei medical journal 12 24142632
2016 Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis. BMC urology 11 27578166
2016 The T>A (rs11646213) gene polymorphism of cadherin-13 (CDH13) gene is associated with decreased risk of developing hypertension in Mexican population. Immunobiology 11 27682011
2015 CDH13 and HCRTR2 May Be Associated with Hypersomnia Symptom of Bipolar Depression: A Genome-Wide Functional Enrichment Pathway Analysis. Psychiatry investigation 11 26207136
2015 Variants in SELL, MRPS36P2, TP63, DDB2, CACNA1H, ADAM19, GNAI1, CDH13 and GABRG2 interact to confer risk of acne in Chinese population. The Journal of dermatology 10 25573302
2020 Genome-wide association study identifies CDH13 as a susceptibility gene for rhododendrol-induced leukoderma. Pigment cell & melanoma research 9 32558222
2018 Loss of Cardio-Protective Effects at the CDH13 Locus Due to Gene-Sleep Interaction: The BCAMS Study. EBioMedicine 9 29903569
2016 CDH13 gene-by-PM10 interaction effect on lung function decline in Korean men. Chemosphere 9 27839881
2015 Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer. Asian Pacific journal of cancer prevention : APJCP 9 25735345
2016 Chromosome 16q genes CDH1, CDH13 and ADAMTS18 are correlated and frequently methylated in human lymphoma. Oncology letters 8 27900031
2009 [Methylation status of JunB and CDH13 gene promoter in CD34(+)CD38(-) chronic myelogenous leukemia cells]. Zhongguo shi yan xue ye xue za zhi 8 20030915
2022 Hsa_circ_0000119 promoted ovarian cancer development via enhancing the methylation of CDH13 by sponging miR-142-5p. Journal of biochemical and molecular toxicology 7 36482494
2021 Familial Psychosis Associated With a Missense Mutation at MACF1 Gene Combined With the Rare Duplications DUP3p26.3 and DUP16q23.3, Affecting the CNTN6 and CDH13 Genes. Frontiers in genetics 7 33897758
2020 CDH13 and LPHN3 Gene Polymorphisms in Attention-Deficit/Hyperactivity Disorder: Their Relation to Clinical Characteristics. Journal of molecular neuroscience : MN 7 32691279
2016 Genetic variants of CDH13 determine the susceptibility to chronic obstructive pulmonary disease in a Chinese population. Acta pharmacologica Sinica 7 26806298
1998 A GT dinucleotide repeat polymorphism in intron 1 of the H-cadherin (CDH13) gene. Journal of human genetics 7 9852687
2025 T-Cadherin (CDH13) and Non-Coding RNAs: The Crosstalk Between Health and Disease. International journal of molecular sciences 6 40649905
2024 The Role of T-Cadherin (CDH13) in Treatment Options with Garcinol in Melanoma. Cancers 6 38791932
2020 Relationship between Methylation of FHIT and CDH13 Gene Promoter Region and Liver Cancer. Current medical science 6 32474857
2016 The effect of celecoxib on DNA methylation of CDH13, TFPI2, and FSTL1 in squamous cell carcinoma of the esophagus in vivo. Anti-cancer drugs 6 27400374
2014 Association study of ARL15 and CDH13 with T2DM in a Han Chinese population. International journal of medical sciences 6 24688318
2005 T-/H-cadherin (CDH13): a new marker for differentiating podocytes. Virchows Archiv : an international journal of pathology 6 16133358
2024 Droplet digital PCR analysis of CDH13 methylation status in Slovak women with invasive ductal breast cancer. Scientific reports 5 38926485
2015 Revealing the Strong Functional Association of adipor2 and cdh13 with adipoq: A Gene Network Study. Cell biochemistry and biophysics 5 25388841
2024 Potassium dehydroandrographolide succinate regulates the MyD88/CDH13 signaling pathway to enhance vascular injury-induced pathological vascular remodeling. Chinese journal of natural medicines 4 38278560
2016 Pharmacogenetics of stimulant abuse liability: association of CDH13 variant with amphetamine response in a racially-heterogeneous sample of healthy young adults. Psychopharmacology 4 27771748
2015 Differential Associations between CDH13 Genotypes, Adiponectin Levels, and Circulating Levels of Cellular Adhesive Molecules. Mediators of inflammation 4 26600672
2010 Methylation of cyclin-dependent kinase inhibitors, XAF1, JUNB, CDH13 and soluble Wnt inhibitors in essential thrombocythaemia. Journal of clinical pathology 4 20364027
2024 Analysis of CDO1, PITX2, and CDH13 Gene Methylation in Early Endometrial Cancer for Prediction of Medical Treatment Outcomes. International journal of molecular sciences 3 38732110
2021 Interactive association between dietary fat and sex on CDH13 cg02263260 methylation. BMC medical genomics 3 33407434
2021 Genome-Wide Association Study on Adiponectin-Mediated Suppression of HDL-C Levels in Taiwanese Individuals Identifies Functional Haplotypes in CDH13. Genes 3 34680977
2017 Genetic variation in CDH13 gene was associated with non-small cell lung cancer (NSCLC): A population-based case-control study. Oncotarget 3 29416663
2012 [5-aza-2'-deoxycytidine-induced inhibition of CDH13 expression and its inhibitory effect on methylation status in human colon cancer cells in vitro and on growth of xenograft in nude mice]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 3 22490847
2024 Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia. Cell death & disease 2 39179585
2023 Association of the CDH13 gene variant rs9940180 with schizophrenia risk in North Indian population. American journal of translational research 2 38074818
2017 The association of six single nucleotide polymorphisms and their haplotypes in CDH13 with T2DM in a Han Chinese population. Medicine 2 28562572
2025 An interplay of non-coding RNAs regulates CDH13 expression and affects endothelial function and coronary artery disease risk. Research square 1 40894025
2019 A potential role for the CDH13/CDH15 gene in repeat revascularization after first percutaneous coronary intervention. Pharmacogenomics 1 31854260
2015 [Single Nucleotide Polymorphisms in T-Cadherin Gene (CDH13) Have Cumulative Effect on Body Mass in Patients With Ischemic Heart Disease]. Kardiologiia 1 27125099